BioCentury
ARTICLE | Financial News

Repligen in precarious waters after GE launches in-house resin

September 26, 2017 10:25 PM UTC

Repligen Corp. (NASDAQ:RGEN) sank $6.24 (14%) to $36.98 Tuesday after Jefferies analyst Brandon Couillard wrote in a note that the rollout of GE Healthcare's newly launched protein A chromatography resin for mAb purification would have negative long-term implications for the bioprocessing company. GE Healthcare is a unit of General Electric Co. (NYSE:GE).

Repligen has manufactured protein A ligands for GE for at least 17 years, which in turn produces and sells protein A resins to biomanufacturers. GE is Repligen's largest customer, accounting for 29% of revenues in 2016. ...